With a focus on optimizing production potential, ARTMS will continue the development of cyclotron-produced 68 Ga and other vitally important medical isotopes, while also pursuing multiple regulatory approvals. ARTMS has a variety of solid targets commercially available used in combination with ARTMS’ QUANTM Irradiation System (QIS™).
About ARTMS
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Based in Vancouver, British Columbia, Canada, ARTMS Inc. is a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System TM (QIS TM ), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 ( 68 Ga), zirconium-89 ( 89 Zr), technetium‐99m ( 99m Tc) and copper-64 ( 64 Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.
SOURCE: ARTMS Inc.
Back to HCB News
